摘要
目的 :观察肝动脉化疗栓塞术 (HACE)联合中药肝癌Ⅰ、Ⅱ号治疗中、晚期肝癌的临床疗效。方法 :中、晚期肝癌患者 60例 ,随机分为两组 ,A组 30例 ,应用HACE联合中药肝癌Ⅰ号 (口服 )、Ⅱ号 (外敷 )治疗 ;B组 30例仅用HACE治疗。全部患者均随访 3年以上。结果 :0 5、1、2年生存率A组分别为 76 7%、56 7%、30 0 % ,B组分别为 50 0 %、33 3%、16 7%。 1、2年复发率A组分别为 4 3 3%、66 7% ,B组分别为66 7%、90 0 %。肿瘤缩小、甲胎球蛋白降低、外周血WBC下降程度A组均明显优于B组 (P <0 0 1)。在临床症状改善方面A组患者比B组患者更明显。结论 :本法对中。
Objective: To observe the clinical effect of combined treatment of hepatic artery chemoembolization (HACE) and Chinese herbal medicine (CHM) in treating middle advanced stage liver cancer. Methods: Sixty patients with middle advanced stage liver cancer were randomly divided into two groups. The 30 patients in Group A were treated with combined HACE and Chinese herbal medicine (Gan′ai No. Ⅰ and No. Ⅱ) and the other 30 in Group B were treated with HACE alone. All patients were followed up for over 3 years. Results: The 0.5 , 1 and 2 year survival rate in Group A was 76.7%, 56.7% and 30.0% respectively, and those in Group B was 50.0%, 33.3% and 16.7% respectively. The 1 and 2 year recurrence rate in Group A was 43.3%, 66.7% and that in Group B was 66.7%, 90.0% respectively. Moreover, Group A was significantly superior to Group B in tumor shrinking, AFP decreasing and blood leucocyte reducing (P<0 01), as well as in improving clinical symptoms. Conclusion: The combined treatment has obvious effect in treating middle advanced stage liver cancer.
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2001年第3期168-170,共3页
Chinese Journal of Integrated Traditional and Western Medicine
关键词
中晚期肝癌
化疗栓塞术
肝癌I号
中医药疗法
肝癌Ⅱ号
middle advanced stage liver cancer, chemoembolization, Chinese herbal medicine Gan′ai No. Ⅰ and No.Ⅱ
